Figure 1.

Trial design. Clinical response is defined as patients achieving Investigator’s Global Assessment score of 0/1 or at least 75% reduction in the Eczema Area and Severity Index. AD, atopic dermatitis; Q2W, every 2 weeks; Q4W, every 4 weeks; TCS, topical corticosteroids.